Acne fulminans
DOI:
https://doi.org/10.35954/SM2025.44.1.4.e402Keywords:
Acne Fulminans, Acne Vulgaris, Acneiform Eruptions, Isotretinoin.Abstract
Introduction: Acne fulminans is a rare and severe variant of Acne vulgaris characterized by the abrupt appearance of skin lesions of different entity and distribution, sometimes accompanied by severe systemic manifestations that require hospitalization of the patient. Its diagnosis requires a high level of suspicion, its etiopathogenic mechanisms have not been elucidated and there are no clear clinical guidelines for its treatment.
Materials and methods: We conducted a literature review in MedLine/PubMed, Lilacs, Scielo and Ibecs in English, Portuguese and Spanish from 2009 to date.
Objective: To describe the etiopathogenic mechanisms and secondarily to know the treatments used in the last 15 years.
Results: 65 articles were reviewed and 36 were selected for analysis. There is no mention of a comprehensive approach to the patient with Acne fulminans regarding the psychoemotional aspects of treatment in most of the articles analyzed.
Discussion: The main trigger linked to the etiopathogenesis of Acne fulminans is the patient's previous exposure to isotretinoin treatment, although autoimmune, inflammatory, hereditary and hormonal mechanisms were also described. Although treatment was directed towards these mechanisms, it was not carried out in a standardized manner.
NOTE: This article was approved by the Editorial Committee.
Received for review: September 2024.
Accepted for publication: December 2024.
Correspondence: Regimiento de Caballería Mecanizado Nº 4. Av. Don Pedro de Mendoza 5801, C.P. 12400. Montevideo, Uruguay. Tel: (+598) 22223004.
Contact e-mail: claudiajimenezuy@gmail.com
Downloads
Metrics
References
(1) Peleg H, Koslowski B, Hiller N, Heyman SN. Radiologic features of acne fulminans. Isr Med Assoc J 2014 Jun; 16(6):393-4. PMID: 25059007.
(2) Marron SE, Gracia-Cazaña T, Miranda-Sivelo A, Lamas-Diaz S, Tomas-Aragones L. Screening for Body Dysmorphic Disorders in Acne Patients: A Pilot Study. Actas Dermosifiliogr (Engl Ed). 2019 Jan-Feb; 110(1):28-32. DOI: 10.1016/j.ad.2018.08.001. Epub 2018 Oct 30. PMID: 30389124.
(3) Gutiérrez-Meré R, Tajes I, Diéguez P, Soto-García D, Martínez-Fernández S, Batalla A. Acne Fulminans: A Narrative Review. Actas Dermosifiliogr 2023 Oct; 114(9):763-771. DOI: 10.1016/j.ad.2023.05.018. PMID: 37245603. DOI: https://doi.org/10.1016/j.ad.2023.05.029
(4) Marron SE, Miranda‐Sivelo A, Tomas‐Aragones L, Rodriguez‐Cerdeira C, Tribo‐Boixaro MJ, Garcia‐Bustinduy M, et al. Body dysmorphic disorder in patients with acne: a multicentre study. J Europ Acad Dermatol Venereol 2020; 34(2):370-376. DOI: 10.1016/j.ad.2018.08.001. DOI: https://doi.org/10.1111/jdv.15954
(5) Zaba R, Schwartz R, Jarmuda S, Czarnecka-Operacz M, Silny W. Acne fulminans: explosive systemic form of acne. J Eur Acad Dermatol Venereol 2011 May; 25(5):501-7. DOI: 10.1111/j.1468-3083.2010.03855.x. PMID: 21029206. DOI: https://doi.org/10.1111/j.1468-3083.2010.03855.x
(6) Duchatelet S, Join-Lambert O, Delage M, Miskinyte S, Guet-Revillet H, Lam T, et al. Remission of chronic acne fulminans and severe hidradenitis suppurativa with targeted antibiotherapy. JAAD Case Rep 2019 Jun 8; 5(6):525-528. DOI: 10.1016/j.jdcr.2019.04.001. PMID: 31205996; PMCID: PMC6558272. DOI: https://doi.org/10.1016/j.jdcr.2019.04.001
(7) Kontochristopoulos G, Agiasofitou E, Platsidaki E, Kapsiocha A, Gregoriou S, Rigopoulos D. Successful Treatment of Coexistent Acne Fulminans and Severe Hidradenitis Suppurativa with Adalimumab. Skin Appendage Disord 2021 Jun; 7(4):329-332. DOI: 10.1159/000515002. PMID: 34307485; PMCID: PMC8280433. DOI: https://doi.org/10.1159/000515002
(8) Greywal T, Zaenglein AL, Baldwin HE, Bhatia N, Chernoff KA, Del Rosso JQ, et al. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol 2017 Jul; 77(1):109-117. DOI: 10.1016/j.jaad.2016.11.028. PMID: 28619551. DOI: https://doi.org/10.1016/j.jaad.2016.11.028
(9) Li AW, Antaya RJ. Isotretinoin-induced acne fulminans without systemic symptoms with concurrent exuberant granulation tissue. Pediatr Dermatol 2018 Mar; 35(2):257-258. DOI: 10.1111/pde.13389. Epub 2018 Jan 4. PMID: 29314240.
(10) Gualtieri B, Tonini A, Panduri S, Chiricozzi A, Romanelli M. Acne fulminans associated with lymecycline intake: a case report. Clin Cosmet Investig Dermatol 2018 Aug 3; 11:403-405. DOI: 10.2147/CCID.S158925. PMID: 30122970; PMCID: PMC6082323. DOI: https://doi.org/10.2147/CCID.S158925
(11) Lee G, Ferri-Huerta R, Greenberg KB, Somers KE. Acne fulminans in a transgender boy after an increase in testosterone dosage. JAAD Case Rep 2022 Jan 6; 21:32-34. DOI: 10.1016/j.jdcr.2021.11.029. PMID: 35141385; PMCID: PMC8816645. DOI: https://doi.org/10.1016/j.jdcr.2021.11.029
(12) Tago O, Nagai Y, Matsushima Y, Ishikawa O. A case of acne fulminans successfully treated with cyclosporin a and prednisolone. Acta Derm Venereol 2011 May; 91(3):337-8. DOI: 10.2340/00015555-0796. PMID: 21369677. DOI: https://doi.org/10.2340/00015555-0796
(13) Perez M, Navajas-Galimany L, Antunez-Lay A, Hasson A. When strength turns into disease: acne fulminans in a bodybuilder. An Bras Dermatol 2016 Sep-Oct; 91(5):706. DOI: 10.1590/abd1806-4841.20165345. PMID: 27828663; PMCID: PMC5087248. DOI: https://doi.org/10.1590/abd1806-4841.20165345
(14) Oranges T, Insalaco A, Diociaiuti A, Carnevale C, Strippoli R, Zambruno G, et al. Severe osteoarticular involvement in isotretinoin-triggered acne fulminans: two cases successfully treated with anakinra. J Eur Acad Dermatol Venereol 2017 Jun; 31(6):e277-e279. DOI: 10.1111/jdv.14022. DOI: https://doi.org/10.1111/jdv.14022
(15) Barry KK, Neale HD, Hawryluk EB. Tumor necrosis factor-alpha inhibitors and acne fulminans: Friend or foe? Pediatr Dermatol 2023 Jul-Aug; 40(4):678-680. DOI: 10.1111/pde.15226. PMID: 36573468. DOI: https://doi.org/10.1111/pde.15226
(16) Trave I, Donadoni R, Cozzani E, D'Agostino F, Herzum A, Parodi A. Acne fulminans and its multiple associated factors: a systematic review. Eur J Dermatol 2023 Dec 1; 33(6):624-634. DOI: 10.1684/ejd.2023.4629. PMID: 38465543. DOI: https://doi.org/10.1684/ejd.2023.4629
(17) Greywal T, Kusari A, Han AM, Borok J, Proudfoot JA, Ahluwalia J, Friedlander SF. Severe acne and its variants: Exploring its natural history and heritability. Pediatr Dermatol 2022 Jul; 39(4):535-540. DOI: 10.1111/pde.14990. PMID: 35584791. DOI: https://doi.org/10.1111/pde.14990
(18) Picone V, Potestio L, Fabbrocini G, Monfrecola G, Marasca C. A case of acne fulminans successfully treated with photodynamic therapy. Photodermatol Photoimmunol Photomed 2022 Jul; 38(4):401-403. DOI: 10.1111/phpp.12761. PMID: 34919759. DOI: https://doi.org/10.1111/phpp.12761
(19) Alramthan A, Abdulkader A, Al-Rushood A. Acne fulminans and isotretinoin. Eur J Dermatol 2019 Aug 1; 29(4):438-439. DOI: 10.1684/ejd.2019.3574. PMID: 31290393. DOI: https://doi.org/10.1684/ejd.2019.3574
(20) Wakabayashi M, Fujimoto N, Uenishi T, Danno K, Tanaka T. A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory bowel disease. Dermatology 2011; 222(3):231-5. DOI: 10.1159/000324226. PMID: 21540556. DOI: https://doi.org/10.1159/000324226
(21) Siadat AH, Bostakian A, Abtahi-Naeini B, Shahbazi M. Successful Treatment of Facial Acne Fulminans: Antimicrobial Agents and Oral Prednisolone as Promising Regimes. Case Rep Dermatol Med 2017; 2017:7092910. DOI: 10.1155/2017/7092910. PMID: 28428896; PMCID: PMC5385906. DOI: https://doi.org/10.1155/2017/7092910
(22) Massa AF, Burmeister L, Bass D, Zouboulis CC. Acne Fulminans: Treatment Experience from 26 Patients. Dermatology 2017; 233(2-3):136-140. DOI: 10.1159/000473860. PMID: 28768255. DOI: https://doi.org/10.1159/000473860
(23) Gualtieri B, Panduri S, Chiricozzi A, Romanelli M. Isotretinoin-triggered acne fulminans: a rare, disabling occurrence. G Ital Dermatol Venereol 2020 Jun; 155(3):361-362. DOI: 10.23736/S0392-0488.18.06013-3. PMID: 30229637. DOI: https://doi.org/10.23736/S0392-0488.18.06013-3
(24) Fakih A, Goens J, Grozdev I, Dangoisse C, Richert B. Acne fulminans induced by a low dose isotretinoin: case report and review of the literature. Dermatol Online J 2020 Dec 15; 26(12):13030/qt14h2419w. PMID: 33423422. DOI: https://doi.org/10.5070/D32612051358
(25) Gier H, Israeli A, Cusick A, Merritt D. Use of Interleukin-12/23 Inhibitor for the Management of Acne Fulminans. Cureus 2023 Dec 11;15(12):e50352. DOI: 10.7759/cureus.50352. PMID: 38205472; PMCID: PMC10781583. DOI: https://doi.org/10.7759/cureus.50352
(26) Leal A, Wood I. Alerta Farmacovigilancia: Isotretinoína: Introducción de nuevas medidas de seguridad, incluida la supervisión adicional del inicio del tratamiento para pacientes menores de 18 años. Boletín Farmacológico 2024; 15(1):1-5. Disponible en: https://www.colibri.udelar.edu.uy/jspui/bitstream/20.500.12008/43784/1/Leal%20y%20Wood.%20Alerta%20Farmacovigilancia%20Isotretinona%20%5b...%5d.pdf
(27) Dessinioti C, Dréno B, Bettoli V, Vural S, Brzezinski P, Nassif A, Svensson Å, Zouboulis CC. Isotretinoin-associated acne fulminans: A multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2024 Jan; 38(1):197-204. DOI: 10.1111/jdv.19477. PMID: 37643921. DOI: https://doi.org/10.1111/jdv.19477
(28) Minardi EP. Dapsona como opción terapéutica en el tratamiento de acné fulminans por isotretinoína. Rev OFIL ILAPHAR [Internet]. 2022 Mar [citado 25 Set 2024]; 32(1):103-104. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2022000100020&lng=es. DOI: 10.4321/s1699-714x20220001000020.
(29) Taudorf EH, Jensen MB, Bouazzi D, Sand C, Thomsen SF, Jemec GBE, et al. Tumor necrosis factor-α inhibitor treatment of acne fulminans - a clinical and literature review. J Dtsch Dermatol Ges 2024 Jan; 22(1):23-27. DOI: 10.1111/ddg.15234. PMID: 38128111. DOI: https://doi.org/10.1111/ddg.15234
(30) Rajaii R, Globerson J, Arnold N, Mahon M. A Novel Treatment of Acne Fulminans with Adalimumab: A Case Report. Spartan Med Res J 2018 Sep 26; 3(2):7003. DOI: 10.51894/001c.7003. PMID: 33655144; PMCID: PMC7746097. DOI: https://doi.org/10.51894/001c.7003
(31) Nasseh J, Brun A, Theret V, Ramspacher J, Severino-Freire M, Coustou D, et al. Efficacy of tumor necrosis factor-alpha inhibitors in the treatment of isotretinoin-induced acne fulminans. J Eur Acad Dermatol Venereol 2024 Jan; 38(1):e96-e98. DOI: 10.1111/jdv.19446. PMID: 37595985. DOI: https://doi.org/10.1111/jdv.19446
(32) Marasca C, Fabbrocini G, Abategiovanni L, Camela E, Nocerino M, Di Guida A, et al. Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case. Skin Appendage Disord 2021 Feb; 7(2):115-119. DOI: 10.1159/000512032. PMID: 33796557; PMCID: PMC7991494. DOI: https://doi.org/10.1159/000512032
(33) Divya BL, Rao PN. SAPHO syndrome with acne fulminans and severe polyosteitis involving axial skeleton. Indian Dermatol Online J 2016 Sep-Oct; 7(5):414-417. DOI: 10.4103/2229-5178.190495. PMID: 27730042; PMCID: PMC5038107. DOI: https://doi.org/10.4103/2229-5178.190495
(34) Feola H, Luna Cian R, Mancinelli MC, Cordoba LM, Crespi C. PASH syndrome: A novel MEFV mutation variant with excellent response to adalimumab in a refractory case. Int J Dermatol 2025 Jan; 64(1):183-185. DOI: 10.1111/ijd.17330. PMID: 38880986. DOI: https://doi.org/10.1111/ijd.17330
(35) Sánchez-Velázquez A, Falkenhain-López D, Arroyo-Andrés J, Montero-Menárguez J, García-Donoso C, Postigo-Llorente C. Apremilast: A novel adjuvant treatment for refractory isotretinoin-induced acne fulminans. Dermatol Ther 2022 Aug; 35(8):e15637. DOI: 10.1111/dth.15637. PMID: 35703093. DOI: https://doi.org/10.1111/dth.15637
(36) Armijo D, Molina MT. Acné Fulminans inducido por isotretinoína, un desafío terapéutico / Isotretinoin-induced acné fulminans: a therapeutic challenge. Rev chil dermatol 2019; 35(1):25-27. Disponible en: https://www.rcderm.org/index.php/rcderm/article/view/202/216 [Consulta 21/08/2024]. DOI: https://doi.org/10.31879/rcderm.v35i1.202
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 : Adriana De Abreu, Andrea Martins, María Pérez y Claudia Jimenez. The author retains his copyright and grants the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
